Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

Détails

ID Serval
serval:BIB_4469142B747F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
Périodique
The Lancet. Neurology
Auteur(s)
Frisoni G.B., Boccardi M., Barkhof F., Blennow K., Cappa S., Chiotis K., Démonet J.F., Garibotto V., Giannakopoulos P., Gietl A., Hansson O., Herholz K., Jack C.R., Nobili F., Nordberg A., Snyder H.M., Ten Kate M., Varrone A., Albanese E., Becker S., Bossuyt P., Carrillo M.C., Cerami C., Dubois B., Gallo V., Giacobini E., Gold G., Hurst S., Lönneborg A., Lovblad K.O., Mattsson N., Molinuevo J.L., Monsch A.U., Mosimann U., Padovani A., Picco A., Porteri C., Ratib O., Saint-Aubert L., Scerri C., Scheltens P., Schott J.M., Sonni I., Teipel S., Vineis P., Visser P.J., Yasui Y., Winblad B.
ISSN
1474-4465 (Electronic)
ISSN-L
1474-4422
Statut éditorial
Publié
Date de publication
08/2017
Peer-reviewed
Oui
Volume
16
Numéro
8
Pages
661-676
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics.

Mots-clé
Alzheimer Disease/diagnosis, Biomarkers, Early Diagnosis, Humans, Validation Studies as Topic
Pubmed
Web of science
Création de la notice
15/08/2017 12:24
Dernière modification de la notice
03/03/2018 16:43
Données d'usage